| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.4 | 0.1 |
| Net income | -23.1 | -19.4 |
| EPS (diluted, $ a share) | $-0.32 | $-0.29 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +359.3% |
|---|
10-Q filed with the SEC, NASDAQ: PLSE. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Pulse Biosciences, Inc.: key numbers
- Share price
- $46.36Close, Nov 16
- Market cap
- $3.41B
- Shares outstanding
- 73.55MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Pulse Biosciences, Inc.
All →Pulse Biosciences Clinical Trial Data
Pulse Biosciences announced interim six-month results from its PRECISE-BTN multicenter U.S. study evaluating the nPulse Vybrance Percutaneous Electrode System for benign thyroid nodules. The data showed that 86% of patients achieved the primary endpoint of at least 50% nodule volume reduction, with a median reduction of 72% and no serious adverse events reported. These results demonstrate the safety and efficacy of the company's nonthermal Nanosecond Pulsed Field Ablation (nsPFA) technology in a clinical setting.
Pulse Biosciences Financial Results
Pulse Biosciences reported third quarter 2026 financial results, highlighted by the completion of enrollment in its NANOPULSE-AF U.S. pivotal IDE study three months ahead of schedule. The company ended the quarter with $189.2 million in cash and equivalents, bolstered by $95.8 million in net proceeds raised through its ATM programs during the period.
“Pulse Biosciences delivered several major milestones since the second quarter, led by completing enrollment in our U.S. pivotal IDE study in just six months, three months ahead of plan. That speed reflects the growing enthusiasm physicians have shown for the nPulse catheter since their very first cases.”
Paul LaViolette, CEO and Co Chairman of Pulse Biosciences
“With NANOPULSE-AF fully enrolled, and the capital to execute, we are now focused on preparations for launch readiness, additional data readouts, and regulatory submissions.”
Paul LaViolette, CEO and Co Chairman of Pulse Biosciences
Pulse Biosciences Partnership with Clayman Thyroid Center at the Hospital for Endocrine Surgery
Pulse Biosciences has entered into a commercial and clinical partnership with the Clayman Thyroid Center to utilize the nPulse Vybrance Percutaneous Electrode System for treating benign thyroid nodules. The collaboration involves the commercial use of the system at the Tampa-based center and a joint effort to collect real-world clinical outcomes and conduct formal studies on nsPFA energy utility.
- Counterparty
- Clayman Thyroid Center at the Hospital for Endocrine Surgery
Pulse Biosciences Clinical Trial Data
Pulse Biosciences reached its enrollment target of 164 evaluable patients in the NANOPULSE-AF IDE pivotal clinical study three months ahead of schedule. The study evaluates the safety and effectiveness of the nPulse Cardiac Catheter System for treating drug-resistant paroxysmal atrial fibrillation. Primary safety and effectiveness endpoints will be assessed at 6 and 12 months post-ablation to support future regulatory submissions.
Pulse Biosciences Other 8-K Filing
Pulse Biosciences entered into a new equity distribution agreement with Mizuho Securities to establish an at-the-market (ATM) offering program for up to $85 million in common stock. This new facility replaces a previous August 2026 ATM program under which the company sold approximately $68.8 million in shares. As of this filing, no shares have been sold under the new $85 million agreement.
- Counterparty
- Mizuho Securities USA LLC
Pulse Biosciences Clinical Trial Data
Pulse Biosciences announced the completion of patient enrollment in its PRECISE-BTN clinical study, which evaluated the nPulse Vybrance Percutaneous Electrode System for treating symptomatic benign thyroid nodules. The study was expanded from 50 to 100 patients across three U.S. sites, and the first patient has already completed the final 12-month follow-up visit. Preliminary data is expected to be presented at an upcoming medical conference.